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The effectiveness of the Complete Health Improvement 
Program (CHIP) in Australasia for reducing selected chronic 
disease risk factors: a feasibility study 
Darren P Morton, Paul Rankin, Peter Morey, Lillian Kent, Trevor Hurlow, 
Esther Chang, Hans Diehl. 
Abstract 
Aim To examine the effectiveness within the Australasian context of the Complete 
Health Improvement Program (CHIP) lifestyle intervention, which has been shown to 
produce meaningful reductions in selected chronic disease risk factors in the United 
States.  
Methods Changes in body weight, blood pressure, blood lipid profile and fasting 
plasma glucose were assessed in 836 self-selected participants (age=55.9±12.7 yrs, 
35% male/65% female) from 18 sites throughout New Zealand (N=731) and Australia 
(N=105).  
Results In the 30 days of the program, significant overall reductions (p<0.001) were 
recorded in the participants’ body mass (-3.8%; 87.1±22.4 versus 83.9±21.5 kg), 
systolic blood pressure (-5.6%; 135±19 versus 127±17 mmHg), diastolic blood 
pressure (-4.6%; 80±12 versus 76±12 mmHg), total cholesterol (-14.7%; 5.17±1.08 
versus 4.41±0.96 mmol/L), low-density lipoprotein cholesterol (-17.9%; 3.17±0.95 
versus 2.60±0.83 mmol/L), triglycerides (-12.5%; 1.51±0.98 versus 1.32±0.71 
mmol/L) and fasting plasma glucose (-5.6%; 5.55±1.49 versus 5.24±1.11 mmol/L). 
Participants at program entry with the highest classifications of total cholesterol, low-
density lipoprotein, triglycerides and fasting plasma glucose experienced over 20% 
reductions in these measures in 30 days.  
Conclusions Significant reductions in selected chronic disease risk factors were 
observed in 30 days using the CHIP intervention and the improvements were 
comparable to that observed in cohorts from the United States. The results of this 
feasibility study indicate that lifestyle interventions like CHIP may be useful for 
combating the burgeoning epidemic of chronic disease and further research is 
warranted. 
Chronic diseases are the major cause of death and disability throughout Australasia 
and are a burden on sufferers, carers, communities and the population at large.1 There 
is an increasing awareness that Lifestyle Medicine, which involves the application of 
environmental, behavioural and motivational principles to the management of lifestyle 
related health problems,2 is efficacious for the primary, secondary and even tertiary 
prevention of chronic diseases.  
The Complete Health Improvement Program (CHIP) is an intensive, community-
based lifestyle intervention that originated in the United States and has demonstrated 
significant benefits for the management of cardiovascular disease,3–5 type 2 diabetes 
mellitus5 and depression.6,7  
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The 30-day program, involving 16 group sessions, encourages participants to move 
towards a distinctive plant-based diet, become physical activity, abstain from 
substance use and practice stress management techniques.  
The objective of the CHIP intervention is to educate and empower individuals 
towards intelligent self-care through enhanced understanding of the epidemiology and 
aetiology of many chronic diseases while providing the skills and support to enable 
positive behaviour change.3 
The CHIP intervention has been delivered in a variety of community settings by both 
health professionals4 and non-health trained volunteers who were equipped with a 
comprehensive package for delivering the program.5 It is estimated that over 50,000 
individuals have completed the program in the United States.8  
The aim of this study was to examine the potential effectiveness of the CHIP 
intervention in the Australasian context for reducing selected risk factors for chronic 
disease.  
Methods 
The study examined the changes in selected chronic disease risk factors of 836 individuals (age = 
55.9±12.7 yrs, 35% male/65% female) who chose to participate in one of 31 CHIP interventions 
presented in 18 locations throughout Australasia (731 participants from 14 sites in New Zealand and 
105 participants from 4 Australian sites).  
The programs ranged in size from 5 to 101 participants (mean group size = 26.3±23.0). Consent for the 
study was obtained from Avondale College of Higher Education Human Research Ethics Committee 
(Approval No. 20:10:07). Participants were encouraged to engage in the program in consultation with 
their personal health care provider.  
The CHIP interventions were advertised in the local media (newspapers, radio) of the communities in 
which the programs were being offered and in some instances local medical practitioners recommended 
their patients to the program. Of the 836 participants who enrolled in the program, 790 (94%) 
completed the 30-day intervention after which they were encouraged to join a support group that met 
monthly.  
Participants were deemed to have completed the program if they attended 13 of the 16 sessions and 
underwent both pre and post-intervention blood testing. As shown in Table 1, at program entry the 
participants were representative of an at-risk population with a mean BMI in the ‘obese’ category (31.2 
kg/m2), borderline ‘prediabetic’ fasting plasma glucose (FPG) levels (5.55 mmol/L), and elevated 
systolic blood pressure (134.8 mmHg) and low-density lipoprotein (LDL) cholesterol levels (3.17 
mmol/L).  
The programs were facilitated by volunteer directors (age = 55.1±9.5, 5 males/13 females) who had an 
interest in positively influencing the health of members of their local community. The volunteer 
directors were not required to be health professionals, although 6 of the 18 were.  
All directors underwent two days of training to develop group facilitation skills after which they were 
provided with a comprehensive CHIP resource package that included a curriculum guide for program 
delivery, 16 pre-recorded educational lectures presented by qualified experts, a cookbook and 
participant textbook and journal. The role of the volunteer director was to organise and facilitate the 
proceedings of the group sessions, not to educate. Even in the case that the director had medical 
training, the supplied resources were used and the program delivery was consistent.  
The CHIP intervention involved 16 two-hour group sessions over 30 days. Each session typically 
involved viewing a one-hour pre-recorded lecture, a cooking demonstration, group discussion and a 
behaviour change challenge. Also incorporated into the program when local health experts could be 
sourced were shopping tours, nutrition workshops and guided exercise sessions. Participants paid a fee 
of approximately $250 to cover the cost of venue hire, food samples distributed throughout the 
program, resources including reading materials and pedometer, and biomedical assessments. 
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Table 1. Mean changes in selected chronic diseases risk factors from baseline to 
post-intervention 
 
Factor N Baseline 
Mean (SD) 
Post-intervention 
Mean (SD) 
Mean 
Change 
% 
Change 
t statistic p value 
Weight (kg) 
BMI (kg/m2) 
SBP (mmHg) 
DBP (mmHg) 
TC (mmol/L) 
LDL (mmol/L) 
HDL (mmol/L) 
TG (mmol/L) 
FPG (mmol/L) 
790 
718 
787 
787 
779 
775 
779 
778 
772 
87.1 
31.2 
134.8 
80.0 
5.17 
3.17 
1.32 
1.51 
5.55 
(22.4) 
(7.7) 
(19.0) 
(11.5) 
(1.08) 
(0.95) 
(0.36) 
(0.98) 
(1.49) 
83.9 
30.0 
127.4 
76.3 
4.41 
2.60 
1.21 
1.32 
5.24 
(21.5) 
(7.4) 
(16.7) 
(11.5) 
(0.96) 
(0.83) 
(0.32) 
(0.71) 
(1.11) 
-3.2 
-1.2 
-7.6 
-3.7 
-0.76 
-0.57 
-0.11 
-0.19 
-0.31 
-3.8% 
-3.8% 
-5.6% 
-4.6% 
-14.7% 
-17.9% 
-8.3% 
-12.5% 
-5.6% 
37.5 
37.2 
13.4 
10.7 
30.0 
26.1 
15.8 
6.7 
7.6 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
BMI – Body mass index; SBP – systolic blood pressure; DBP – diastolic blood pressure; TC – Total cholesterol; 
LDL – low density lipoprotein; HDL – high density lipoprotein; TG – triglycerides; FPG – fasting plasma glucose; 
SD – Standard deviation. 
 
The CHIP intervention advocated daily exercise (30 minutes of moderate intensity or 10,000 steps) and 
included elements of positive psychology, but nutrition was the focus of the program. The intervention 
advocated a distinctive eating pattern as participants were encouraged to move towards a whole food, 
plant-based diet ad libitum, with emphasis on the consumption of whole-grains, legumes, fresh fruits 
and vegetables. This diet was recommended in order to achieve a daily target of fewer than 20% of 
calories from fat and less than 10 teaspoons of added sugar, 5,000 mg of salt (2000 mg of sodium) and 
50 mg of cholesterol. Participants were also encouraged to consume 2 - 2.5 litres of water daily.3  
At the beginning and end of the program the participants’ height, weight, blood pressure and 12-hour 
fasting blood samples were taken. The blood samples were collected by trained phlebotomists and 
analysed by local pathology laboratories for total cholesterol (TC), low-density lipoprotein (LDL), 
high-density lipoprotein (HDL), triglycerides (TG) and fasting plasma glucose (FPG) levels.  
Statistical analysis—The data were analysed using PASW™ Statistics (version 18) software. Data are 
expressed as mean ± standard deviation. Paired t-tests were used to assess changes in the biometric 
measures from baseline to post-intervention, both for the overall and stratified data. McNemar Chi-
squared test was used to determine changes from program entry to post-intervention in the distribution 
of participants across the various risk factor categories. Cohen’s d statistic was calculated to present 
effect size. 
Results 
The participants’ mean changes from baseline to post-intervention are presented in 
Table 1. Significant reductions were recorded in all the biometrics with the most 
notable being in TC, LDL and TG. While HDL also decreased following the 
intervention, the TC to HDL ratio improved from 3.92:1 to 3.64:1 (p<0.001). Table 2 
displays the stratified data using conventional risk factor categories. The National 
Cholesterol Education Program Adult Treatment Panel III classification system9 was 
used to categorise the participants for all risk factors except TC. The Framingham 
classification10 was used for the TC data as it includes five categories, compared to 
three in the ATP III classification, thus allowing a more detailed analysis of the effect 
of the intervention on the highest risk participants. 
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Table 2. Changes in chronic disease risk factor levels within 30 days according to initial risk factor classification 
 
Risk Factor N 
Baseline 
N 
Post-intervention 
Chi-
squared* (p) 
 
Baseline 
Mean (SD) 
Post-
intervention 
Mean (SD) 
Mean 
Change 
% Mean 
Change 
p value Cohen’s d 
BMI (kg/m2)            
18.5–24.9 137 168 78 (<0.001) 22.7 (1.6) 22.2 (1.6) -0.6 -2.5% <0.001 0.313 
25–30 216 234  27.5 (1.4) 26.5 (1.4) -1.0 -4.8% <0.001 0.714 
> 30 350 301  36.9 (7.0) 35.5 (6.9) -1.4 -3.8% <0.001 0.201 
SBP (mmHg)            
<120 189 312 120 (<0.001) 112.9 (7.6) 114.2 (11.4) 1.3 1.2% 0.119 -0.134 
120–139 314 297  130.2 (4.9) 125.1 (12.6) -5.1 -3.9% <0.001 0.533 
140–160 226 151  148.9 (6.6) 136.5 (15.4) -12.4 -8.3% <0.001 1.047 
>160 58 27  177.1 (12.7) 147.4 (16.5) -29.7 -16.8% <0.001 2.017 
DBP (mmHg)            
<80 349 446 80 (<0.001) 70.1 (6.5) 70.2 (8.9) 0.1 0.1% 0.872 -0.013 
80–89 277 258  82.9 (2.8) 78.2 (8.5) -4.6 -5.5% <0.001 0.743 
90–100 133 63  93.5 (3.6) 84.2 (9.7) -9.4 -10.1% <0.001 1.271 
>100 28 20  108.8 (5.3) 93.7 (10.9) -15.1 -13.9% <0.001 1.762 
TC (mmol/L)            
< 4.00 93 268 407 (<0.001) 3.49 (0.40) 3.23 (0.55) -0.26 -7.4% <0.001 0.541 
4.00–5.20 334 371  4.62 (0.37) 4.03 (0.59) -0.59 -12.7% <0.001 1.198 
5.21–5.99 172 94  5.59 (0.21) 4.74 (0.63) -0.85 -15.2% <0.001 1.810 
6.00–6.99 143 40  6.39 (0.29) 5.23 (0.74) -1.16 -18.2% <0.001 2.064 
>7.00 37 6  7.62 (0.49) 6.01 (0.99) -1.61 -21.1% <0.001 2.061 
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LDL (mmol/L)            
<2.50 215 381 296 (<0.001) 2.06 (0.41) 1.80 (0.50) -0.26 -12.6% <0.001 0.569 
2.50-2.99 140 171  2.79 (0.14) 2.39 (0.48) -0.40 -14.3% <0.001 1.131 
3.00-4.00 271 181  3.49 (0.29) 2.84 (0.58) -0.64 -18.3% <0.001 1.418 
>4.00 149 42  4.55 (0.45) 3.50 (0.72) -1.05 -23.1% <0.001 1.789 
HDL (mmol/L)            
<1.00 147 201 96 (<0.001) 0.86 (0.10) 0.85 (0.12) -0.01 -1.2% 0.546 0.091 
1.00-1.55 439 470  1.26 (0.16) 1.17 (0.19) -0.09 -7.1% <0.001 0.512 
>1.55 193 108  1.81 (0.23) 1.58 (0.29) -0.24 -13.3% <0.001 0.879 
TG (mmol/L)            
<1.00 233 282 38 (<0.001) 0.75 (0.15) 0.82 (0.29) 0.08 10.7% <0.001 -0.303 
1.00-2.25 433 428  1.47 (0.33) 1.33 (0.48) -0.15 -10.2% <0.001 0.340 
>2.25 112 68  3.21 (1.47) 2.31 (0.98) -0.91 -28.3% <0.001 0.720 
FPG (mmol/L)            
<5.60 530 605 55 (<0.001) 4.91 (0.42) 4.87 (0.56) -0.04 -0.8% 0.067 0.081 
5.60-7.00 177 129  6.02 (0.39) 5.53 (0.55) -0.48 -8.0% <0.001 1.028 
>7.00 65 38  9.47 (2.28) 7.42 (2.27) -2.05 -21.6% <0.001 0.901 
 
BMI – Body mass index; SBP – systolic blood pressure; DBP – diastolic blood pressure; TC – Total cholesterol; LDL – low density lipoprotein; HDL – high density lipoprotein; TG – 
triglycerides; FPG – fasting plasma glucose; SD – Standard deviation. * McNemar Chi-squared test. SD – Standard deviation. 
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Participants who presented to the program with the highest risk factor classifications 
tended to experience the greatest improvements and the effect sizes were large.  
Participants who entered the program with TC levels above 5.2 mmol/L experienced a 
mean reduction of 1.05 mmol/L which, according to the algorithm generated through 
meta-analysis by Gould and colleagues,11 would result in a 19% decrease in the 
relative risk for all-cause mortality, a 26% reduced risk for coronary heart disease 
related mortality and a 31% reduced risk of a cardiac event. 
As shown in Table 2, many of the participants who presented with the highest risk 
factor classifications at program entry had moved to lower risk factor classifications 
by the end of the intervention. Only 6 of the 39 individuals with TC levels above 7.0 
mmol/L at program entry maintained these levels post-intervention. Of the 68 
individuals with FPG levels indicative of diabetes at baseline, 30 (44%) reduced their 
scores below 7.0 mmol/L in the 30 days.  
A comparison of the risk factor reductions observed in this study with those recently 
reported in a cohort of over 5,000 CHIP participants from the United States5 is 
presented in Table 3. Clearly, similar outcomes were observed in this study and the 
United States cohort. 
 
Table 3. Comparison of the mean changes in selected chronic disease risk  
factors from baseline to post-intervention in the present study and CHIP  
participants from the United States 
 
% Change Factor 
Australasian CHIP 
(N=787) 
US CHIP*  
(N=5070) 
BMI 
SBP 
DBP 
TC 
LDL 
HDL 
TG 
FPG 
-3.8% 
-5.6% 
-4.6% 
-14.7% 
-17.9% 
-8.3% 
-12.5% 
-5.6% 
-3.2% 
-4.9% 
-5.3% 
-11.0% 
-13.0% 
-8.6% 
-7.7% 
-6.1% 
BMI – Body mass index; SBP – systolic blood pressure; DBP – diastolic blood pressure; TC – Total cholesterol; 
LDL – low density lipoprotein; HDL – high density lipoprotein; TG – triglycerides; FPG – fasting plasma glucose. 
* From Rankin et al.5 
 
While the low numbers in some of the program groups did not allow statistical 
comparisons, there was considerable variability between the groups in the extent of 
change observed in the outcome measures.  
 
Discussion 
The findings of this Australasian study supports data from the United States, 
suggesting that the CHIP lifestyle intervention appears to produce meaningful 
reductions in selected chronic disease risk factors in the Australasian context. The 
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outcomes observed were comparable between both regions, with the greatest 
reductions among those with the greatest risk. However, caution in the interpretation 
of the findings is required because of a number of limitations. 
Several confounders may explain the magnitude of the changes in the chronic disease 
risk factors observed in this feasibility study. Firstly, as the participants were self-
selected, they likely entered the program with an elevated readiness for change and 
hence willingness to engage in the intervention.  
In accordance with the transtheoretical model of behaviour change,12 a key objective 
of the first few sessions of the CHIP intervention is to move participants from pre-
contemplation to action. Yet the participants were probably beyond the pre-
contemplation stage at program entry. It would be interesting to compare the 
outcomes observed in this study with participants who had not shown an initial 
interest in the program. 
Secondly, in the absence of a control group, the extent to which regression to the 
mean explains the observed improvements cannot be determined. Consistent with 
regression to the mean is that the individuals with the most extreme baseline measures 
tended to experience the greatest improvements and hence inclination towards the 
norm. However, given the large size of the sample and that in some of the outcomes 
measures the high risk classifications moved 1.5 to 2 standard deviations, regression 
to the mean likely only explains a small component of the observed results.  
Noteworthy, several studies of the CHIP intervention in the United States have 
demonstrated the effectiveness of the program using a randomised control design and 
the magnitude of change observed in the present study is similar to the treatment 
groups of these studies.4 Certainly, a randomised control trial is need in the 
Australasian setting to extend upon the work done in this feasibility study. 
The final potential confounder of the outcomes observed in this study is the 
Hawthorne effect. While the research team were not responsible for conducting all the 
interventions, the participant’s behaviours and level of engagement with the program 
was undoubtedly influenced by the blood measures taken pre and post-intervention.  
Given that the pre and post blood work is a standard component of the CHIP 
intervention, improvements achieved as a result of these accountability measures 
could be considered part of the intervention itself. However, further research is 
needed to elucidate the influence of the unique lifestyle recommendations of the CHIP 
intervention—namely its emphasis on a whole-food, plant-based eating pattern—from 
the motivational properties of the pre and post-intervention measurements made on 
the participants. Certainly, the inclusion of accountability measures is likely to be an 
important component of lifestyle interventions targeting chronic disease.  
Notwithstanding the limitations in the research design, the results of this feasibility 
study are noteworthy given the size of the sample and the large effect sizes observed. 
Indeed, the results of this study indicate that the CHIP intervention shows promise for 
the management of chronic diseases in the Australasian context.  
It is noteworthy that in only 30 days over 20% improvement was observed in the 
participants with the highest classifications of TC (21%), LDL (23%), TG (28%) and 
FPG (22%). The changes in TC and LDL compare favourably to those achieved by 
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pharmaceutical interventions involving statins11 and far exceed the typical 
expectations of dietary interventions for lowering blood lipids.13  
The large changes observed with the intervention is likely a result of the dietary 
recommendations of CHIP being more extreme than conventional guidelines. Despite 
its rigor, the participants anecdotally reported a high level of acceptability of the 
eating pattern, which was probably enhanced because the diet was not calorically 
restrictive and hence the participants were satiated.  
In the United States, Barnard and colleagues14 reported similar levels of acceptability 
of a plant-based eating pattern to the more moderate diet recommended by the 
American Dietetic Association, although acceptability needs to be determined in the 
Australasian context. 
As described in the results section, a decrease in TC and LDL would offer substantial 
cardio-protection and reduce the relative risk for all-cause mortality. However, while 
the observed decrease in TC and LDL are beneficial, the reduction in HDL appears 
counterproductive. Noteworthy, individuals who adopt a whole-food, plant-based 
eating pattern, which is free from exogenous cholesterol and low in saturated fat, 
typically have lower blood concentrations of all cholesterol subfractions, including 
HDL.15  
Notwithstanding, these individuals do not have compromised cardiovascular health 
and are not at increased risk of type 2 diabetes mellitus.15 In fact, in the Lifestyle 
Heart Trial16 that prescribed a low-fat, plant-based diet, participants experienced 
regression of atherosclerotic plaque and a reduction in cardiac events despite a 
concomitant decrease in HDL levels.  
The lowered HDL levels associated with a plant-based eating pattern may be 
explained by less need for reverse cholesterol transport. Importantly, despite the 
decrease in HDL observed in the present study, the TC to HDL ratio improved.  
There were several anecdotal reports in the present study of participants’ having their 
medications (e.g. hypertensive, hypercholesterolemia, hyperglycaemic) decreased or 
even ceased by their personal doctor during the course of the 30-day intervention. 
While this is a desirable outcome, a reduction in medication usage may have caused 
the results presented in this report to be understated. It is a limitation of this study that 
medication changes were not recorded and this should be included in future studies.  
Given that many chronic diseases have lifestyle underpinnings,1 there is a growing 
awareness that lifestyle interventions have merit at all levels of prevention. In terms of 
primary prevention, results of the 52 country INTERHEART study17 indicated that 
positive lifestyle practices, such as the consumption of fruits and vegetables, being 
physically active and avoiding the use of tobacco, can prevent up to 90% of 
myocardial infarctions.  
With regards to secondary prevention, the Diabetes Prevention Program Research 
Group18 showed a 16-session lifestyle education program to be twice as effective as 
pharmaceuticals (metformin) for preventing at-risk people with pre-diabetes 
developing established diabetes. At the tertiary level, the potential for disease reversal 
is emerging as an area of interest in the field of lifestyle medicine.16,19-22  
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Several studies have explored the potential of lifestyle interventions for chronic 
disease reversal and most have centred around a whole-food, plant-based diet high in 
fibre (>30 grams) and low in fat (<20%), cholesterol and refined sugar. Esselstyn19 
showed regression of heart disease using a low-fat (<10%) plant-based diet alone, 
while the Lifestyle Heart Trial16 demonstrated cardiovascular disease reversal through 
plant-based nutrition combined with exercise, social support and stress management 
techniques.  
Similarly, the role of lifestyle in potential reversal of type 2 diabetes has been known 
for over 30 years.20,21 Barnard and associates22 reported ∼40% of people with type 2 
diabetes treated with insulin could discontinue its use through participation in a 26-
day residential program involving a near vegetarian, low-fat diet in conjunction with 
exercise.  
In the present study, over 40% of participants who entered the program with FPG 
levels indicative of diabetes reduced their levels below this classification in 30 days. 
This observation is comparable to our recent report of over 5,000 CHIP participants 
from the United States.5  
The results observed in this study of a free-living population are encouraging for a 30-
day intervention, however, the question of sustainability remains. Maintenance of 
behaviour change following involvement in the CHIP intervention has been 
documented for up to 18 months in the United States23 but a sustainability study in the 
Australasian context is needed.  
Anecdotally there are numerous case reports of individuals involved in this project 
who experienced continued, and even profound, health improvements beyond their 
involvement in the CHIP intervention. However, achieving long-term compliance to 
interventions that aim to improve patient outcomes over time is a challenge. This is 
the case for both lifestyle or pharmaceutical interventions.24,25  
While the CHIP intervention incorporates elements to promote long-term health 
behaviour change—including education, social support, accountability measures, and 
a focus on one’s environment and how to re-engineer it to support positive lifestyle 
choices—questions surrounding how to optimise engagement with lifestyle 
interventions need to be further explored.  
A greater understanding of what makes lifestyle interventions most efficacious is 
required. For example, while improvements in participants’ biometrics were recorded 
for all groups involved in this study, some groups appeared to achieve better 
outcomes than others. Given the intervention was essentially the same for all groups 
in terms of duration, intensiveness and content, the varying outcomes could 
conceivably be explained by factors relating to either the group participants and/or 
elements of the program that did vary between the groups.  
Participant factors may include age, gender, social class, ethnicity, who they 
participated in the intervention with, baseline health status and the extent of 
engagement with the intervention and the lifestyle recommendations it advocated.  
Other factors may include group size, social class, venue or setting, and 
characteristics relating to the facilitator such as their level of training and experience 
conducting lifestyle interventions. How these factors contribute to the success of a 
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lifestyle intervention remains to be elucidated. Further, it would be interesting to 
study the outcomes of a CHIP intervention conducted in a less intense manner, given 
that the current program involves 16 sessions over a one-month period.  
A unique element of the study was the use of volunteers to administer a professionally 
generated lifestyle intervention. Only one third of the facilitators involved in this 
study had medical or health training, but regardless, all underwent two days of 
training that focused on the logistics of administering the program and providing them 
with group facilitation skills. It was mandated that the facilitators not provide lifestyle 
counsel as this was presented in the pre-recorded educational presentations provided 
as part of the CHIP resource.  
Harnessing the energy of volunteers to facilitate lifestyle interventions, as employed 
in this study, represents a potentially powerful and cost-effective mode for 
administering lifestyle interventions. Many of the volunteer directors of the programs 
in this study had previously participated in a CHIP intervention and therefore had a 
strong investment and bond with the program. Indeed, passionate volunteers can be 
powerful agents of change and possess motivational properties to incite their peers to 
action.26 
Conclusions 
The results of this feasibility study indicate that lifestyle medicine programs like the 
CHIP intervention show promise for the management of selected chronic diseases 
within the Australasian context. Further, volunteers can be valuable social capital in 
the combat of chronic diseases by facilitating well-designed and appropriately 
resourced lifestyle interventions.  
A randomised control trial is warranted that investigates the effectiveness and 
sustainability of the lifestyle choices acquired during the CHIP intervention and the 
associated long-term reductions in chronic disease risk factors. A further investigation 
of the acceptability of the specific nutritional recommendations of the CHIP 
intervention in the Australasian setting is also required.  
Finally, in order to optimise the outcomes achieved by lifestyle interventions such as 
the CHIP, research is required to elucidate how factors relating to the participant as 
well as the structure, content and facilitation of the program contribute to the success 
of the intervention.  
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